This study is testing a new treatment called KK-LC-1 TCR-T cells for people with advanced gastric, breast, cervical, or lung cancer that has spread (metastatic). This treatment uses your own immune cells, called T cells, which are specially trained to find and attack cancer cells that have a protein called KK-LC-1. Before receiving the KK-LC-1 TCR-T cells through a single infusion, you will have a preparation treatment with cyclophosphamide and fludarabine. You will also receive aldesleukin after the cell infusion. The main goal of this study is to find the highest safe dose of KK-LC-1 TCR-T cells. To join, your cancer must show the KK-LC-1 protein, and you must be at least 18 years old. The study plans to enroll 30 participants, but its current status is unclear.

Study design

This is a Phase 1 interventional study to find the maximum tolerated dose of KK-LC-1 TCR-T cells. It plans to enroll 30 participants.

What's involved

Participants will receive a conditioning regimen of cyclophosphamide and fludarabine, followed by a single intravenous infusion of KK-LC-1 TCR-T cells, and then up to 6 doses of aldesleukin.

Compensation

Not stated in the trial record.

Follow-up

The maximum tolerated dose of KK-LC-1 TCR-T cells will be measured at 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.